HALIFAX, Nov. 29 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT) announced today that it has successfully scaled-up the manufacturing process for its vaccine platform, Vaccimax(R). This work validates the suitability of the platform for commercial applications in therapeutic cancer and infectious disease indications. The manufacturing development was performed at Dalton Pharma Services, a Health Canada and GMP compliant pharmaceutical manufacturing and development company. Today’s results show that IVT’s vaccine delivery platform can be produced on a commercial scale.
IVT’s product, VacciMax(R), is a vaccine-enhancement platform comprised of a special emulsion of liposomes, antigens, adjuvants and oil. To prepare VacciMax(R) for human cancer clinical trials, IVT has been developing its platform to meet all regulatory requirements including manufacturing in a GMP setting. The ability to scale-up, under GMP or good manufacturing practices, is mandatory for various worldwide regulatory authorities, such as the FDA. By successfully producing VacciMax(R) at a commercially relevant batch size, IVT plans to license its vaccine technology worldwide for the therapy and prevention of cancer and infectious diseases.
“We are pleased to collaborate with IVT and wish to congratulate the entire team on meeting such an important milestone. The successful scale-up of VacciMax(R) was a direct result of the Dalton and IVT teams’ strong technical capabilities and project management skills,” remarked Peter Pekos, President and CEO of Dalton Pharma Services.
IVT’s testing verified that development batches produced at Dalton at an increasing scale retained their expected biological activity. Analytical testing also showed that the various elements of the platform are chemically stable. The latest batch produced at the 50 litre scale also met manufacturing and chemical specifications.
“VacciMax(R) is a novel technology with broad potential,” said Marc Mansour, Vice President of Research and Development. “Proving that our technology can be manufactured in a GMP environment and is scalable, will enable us to aid the development of vaccines for numerous therapeutic cancer and preventative infectious disease applications”
ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company focused on the commercialization of its patented VacciMax(R) platform. VacciMax(R) is a novel technology that can aid the development of new vaccines in human health applications with potential for both therapeutic cancer applications and preventative infectious disease vaccines. The opportunities for market applications and medical benefits are broad, and are currently being applied to cervical cancer, with potential for melanoma, breast, prostate and colon cancer treatments, as well as prevention therapies for influenza and other infectious diseases. www.immunovaccine.com
CONTACT: Jennifer Ayotte, Communications, (902) 423-6610 x 315,
jayotte@impactcommunications.ca; Brian Lowe, Vice President IVT, (902)
492-1819, bl.ivt@immunovaccine.com